Protocol Details
Internal Jugular Vein Sampling for ACTH Levels for the Differential Diagnosis of Cushing Syndrome
This study is NOT currently recruiting participants.
Summary | Eligibility | Citations | Contacts
Summary
Number |
95-CH-0104 |
Sponsoring Institute |
National Institute of Child Health and Human Development (NICHD) |
Recruitment Detail |
Type: No longer recruiting/follow-up only |
Referral Letter Required |
Yes |
Population Exclusion(s) |
Children |
Special Instructions |
Currently Not Provided |
Keywords |
Petrosal Sinus Sampling; |
Recruitment Keyword(s) |
None |
Condition(s) |
Cushing's Syndrome |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
None |
Supporting Site |
|
The procedure to collect blood from the petrosal sinus is called Inferior Petrosal Sinus Sampling (IPSS). The technique is very sensitive and can tell the difference between a pituitary tumor and other causes of Cushing syndrome nearly 100% of the time. However, IPSS is very difficult to perform and is only available in a few hospitals. Therefore, researchers are looking for another possible way to diagnose Cushing syndrome that would be less technically difficult and more readily available to patients.
ACTH is produced in the pituitary gland as a response to the production of Corticotropin-Releasing Hormone (CRH) in the brain (hypothalamus). This study will compare ACTH levels in the internal jugular veins before and after CRH stimulation with those obtained by conventional IPSS from patients with Cushing's syndrome.
Obtaining blood from the jugular veins is a simple, practically risk free procedure that could be done easily in a community hospital on an out patient basis. Researchers believe that CRH stimulation will increase ACTH production from tumors of the pituitary gland (corticotroph adenomas) so that the diagnostic information from jugular venous sampling would be equivalent to that of IPSS.
This proposal to develop jugular venous sampling (JVS) with CRH stimulation as a test for the differential diagnosis of Cushing Syndrome would potentially contribute greatly to the medical care of patients with Cushing syndrome, as a less costly, safer and more widely available alternative to IPSS.
Eligibility
INCLUSION CRITERIA:
Patients with the following characteristics may be included in the protocol:
Age 18-75 years.
Evidence of Cushing syndrome. Evidence to suggest overactivity of the hypothalamic-pituitary-adrenal axis, such as increased urinary excretion of glucocorticoids or lack of suppressibility with low doses of dexamethasone in conjunction with clinical features, will be sought prior to admission.
EXCLUSION CRITERIA:
Patients will be excluded from entry to the protocol if:
A clear-cut pituitary tumor is present on T1-weighted conventional pituitary MR scan.
There is any contraindication to catheterization. Patients with known reaction to contrast material will be excluded from this elective study if they have a strong history of previous contrast media reaction and cannot be studied safely by giving medical prophylaxis before the procedure.
The patient is pregnant.
Combined blood withdrawal during the six weeks preceding the study exceeds 450 ml, or if hematocrit at entry is less than 33%.
Because of the increased risk of morbidity caused by contrast dyes in patients with a renal dysfunction, patients with a creatinine greater than 1.3 mg/dl will be excluded.
Patients with a diastolic blood pressure persistently greater than 100 mm Hg (with or without medication) will be excluded from sampling procedures.
They have had radiation exposure during the previous year that represents a significant additive risk in combination with the expected doses in this protocol. Patients and their doctors will be questioned about their exposure to radiation before they are accepted into the protocol.
For the questionnaire only, patients who do not speak and read English will be excluded. This instrument has not been validated in non-English speakers.
Citations:
Contacts:
Principal Investigator |
Referral Contact |
For more information: |
| Lynnette K. Nieman, M.D. National Institute of Child Health and Human Development (NICHD) National Institutes of Health Building 10 Room 1-3140 10 Center Drive Bethesda, Maryland 20892 (301) 496-8935 niemanl@cc1.nichd.nih.gov |
Lynnette K. Nieman, M.D. National Institute of Child Health and Human Development (NICHD) National Institutes of Health Building 10 Room 1-3140 10 Center Drive Bethesda, Maryland 20892 (301) 496-8935 niemanl@cc1.nichd.nih.gov |
Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov |
Clinical Trials Number:
NCT00001453
QUESTIONS?
Contact the Patient Recruitment and Public Liaison Office for:
- Details on how to participate in a study
- Details on how to refer a patient to a study
NIH Clinical Studies Information Request
Contact the Office of Communications for:
- General information about the NIH Clinical Center
Contact the Department Clinical Research Informatics, (DCRI) for:
- Technical questions about Adobe Acrobat and the PDF format
- Technical questions about this web server




